Tuesday, March 29, 2022
Educational Session
Impacts of the COVID-19 Pandemic on Advancing HIV, STI and Viral Hepatitis Testing
Megan Crumpler, PhD
Presentation
Overview of HIV Testing Practices and Technology
S. Michele Owen, PhD
Presentation
STI Testing Technology
Barbara Van der Pol, Phd
Presentation
Hepatitis C Virus Test Technology
Saleem Kamili, PhD
Presentation
Debrief of the HCV Diagnostics Conference
Carolyn Wester, MD
Presentation
Opening Session: Testing as a Gateway to Prevention and Care
Moderator:
Jonathan Mermin, MD, MPH
Discussants:
Demaetre Daskalakis, MD
Leandro Mena, MD
Carolyn Wester
Session 1: Nucleic Acid Tests
A Shared Service Model for HIV Nucleic Acid Testing and the Impact of COVID-19
Lauren Johnson, MPH
Presentation
Multisite Evaluation of an HIV-1 panel on the Alinity m HIV-1 assay and its relevance to critical clinical decision points
Whitnie Crown, MS, M(ASCP)MB
Presentation
HIV/HCV Screening, Testing, and Diagnostic Reliability during the Acute Encounter with the Cepheid GeneXpert
Jason Wilson, MD, MA, FACEP
Presentation
Evaluation of the Aptima HCV Quant Dx Assay for qualitative and quantitative RNA detection in Dried Blood Spots
Renee Hallack, BS
Presentation
Validation of new STI panel for Abbott Alinity m
Karen C. Rexroth, M(ASCP)
Presentation
The Clinical and Cost Implications of Using HIV RNA Instead of Antibody Testing to Confirm Reactive HIV Screening Tests in the United States
Daniel Gromer, MD
Presentation
Discussion Panel 1: Using a molecular test as the second test in the HIV diagnostic algorithm
Moderator:
S. Michele Owen, PhD
Discussants:
Bernard Branson, MD
Presentation
Monica Parker, PhD
Presentation
S Berry Bennett, MPH
Presentation
Joseph Yao, MD
Presentation
Jeffery A. Johnson, PhD
Presentation
Wednesday, March 30, 2022
Discussion Panel 2: The utility of multiplex versus singleplex or lower plex testing in STI diagnostics
Moderator
Barbara Van Der Pol, PhD,
Discussants
James Kirby, MD D(ABMM)
Katherine Hsu, MD
Kevin Ard, MD, MPH
Erica Hardy, MD, MMSc
Christina Muzny, MD, MSPH
Session 2: Recently Marketed Tests
2A. Evaluation of the DPP HIV-Syphilis test performance characteristics at the point-of-care clinical setting (FDOH-Miami-Dade STD clinical lab).
Olga V. Ponomareva, MD
Presentation
2B. Performance of the Avioq VioOne HIV Profile Supplemental Assay for Confirmation and Differentiation of HIV-1 and HIV-2 Antibodies at a State Public Health Laboratory.
S. Berry Bennett, MPH
Presentation
2C. Visby Medical Sexual Health Click test: A patient-centric approach to diagnosing sexually transmitted infections
Teresa M. Abraham, PhD
Presentation
Session 3: Optimizing Testing Opportunities
3A. Testing 1-2-3: A Novel Approach to STI/HIV testing in Rhode Island
Siena Napoleon, MPH
Presentation
3B. CDC’s Direct-to-consumer Distribution of 100,000 HIV self-tests
Pollyanna R. Chavez, PhD
Presentation
3C. Infectious Disease Testing at a Syringe Services Program (SSP)
Heather Henderson, MA/CAS
Presentation
3D. Promoting HIV and Hepatitis C Virus Testing and Linkage to Harm Reduction Resources Through Navigation Programs
Shamia Roberts, BSN, RN
Presentation
3E. Optimizing Hepatitis C Virus Screening using Automation in an Urban Emergency Department
Melisa Hart, MPH
Minh Tran, BS
Presentation
Moderator: Jenny R. McFarlane, BA
Discussion Panel 3 – The Reddit Community asks the experts about STIs. Here’s what we discovered…
Moderator
Megan Crumpler, PhD,
Discussants
Barbara Van Der Pol, PhD,
Srishti Baid, MS
Miguel Quiñones-Mateu, PhD
Presentation
Thursday, March 31, 2022
Session 4: Testing Challenges
4A. Biotin Interference in Point of Care HIV Immunoassay
Mohan Kumar Haleyur Giri Setty, PhD
Presentation
4B. Equivocal HIV Screening Results in the Emergency Department. False Positive or Acute Seroconversion?
Jason Wilson, MD, MA, FACEP
Presentation
4C. Longitudinal Specificity of the BioPlex 2200 HIV Ag-Ab Combination Assay in Routine Screening in a US Public Health Laboratory
Alfredo Villarreal, BS, MBA
Presentation
4D. Do COVID antibodies cross-react with the BioPlex 2200 HIV Ag-Ab differentiating combination screening assay?
Payu A. Raval, MD
Presentation
4E. Seroconversion, seroreversion, and serowaffling among participants in Project DETECT
Joanne Stekler, MD
Presentation
Moderator: Richard L. Hodinka, PhD
Discussion Panel 4 – Opportunities and challenges with using HIV recency testing and other metrics to monitor progress towards Ending the HIV Epidemic
Moderator
Kevin Delaney, PhD
Discussants
Shelley Facente, PhD, MPH
Presentation
Kate Mitchell, PhD
Chris Beyrer, MD, MPH
Session 5: Emerging Technology
5A. Development of a serologic assay for differentiating acute from chronic HCV infection
Matthew Pauly, PhD
Presentation
5B. A laboratory-developed quantitative hepatitis B surface antigen (qHBsAg) test detects 8 major HBV genotypes and sG145R mutants
Mary Lape Nixon, BA, MS
Presentation
5C. Time to leave Fiebig staging in the dust? Estimated Dates of Detectable Infection (EDDIs) as a new and improved method for HIV infection dating
Shelley Facente, PhD, MPH
Presentation
5D. Use of the Geenius Index to indicate recent HIV infection in Project DETECT
Lauren Violette, MPH
Presentation
Moderator: Kelly Curtis, PhD
Discussion Panel 5 – Detecting and confirming acute or incident HIV infection in persons taking antiretrovirals for PrEP
Moderator
Dawn Smith, MD
Discussants
Adam Visconti, MD, MPH
Presentation
Raphael Landovitz, MD
Presentation
Susan Eshleman, MD, PhD
Friday, April 1, 2022
Feedback Session: Regulatory Issues Related to Self-collection and Remote Testing (led by FDA and CDC)
Panelists
Julia Lathrop, PhD
Presentation
S. Michele Owen, PhD
Ellen Kersh, PhD
Timothy Stenzel, MD, PhD
Session 6: Mail-in Testing
6A. Addition of Extragenital STI testing in “I Want The Kit” Program Users
Tong Yu, ScM
Presentation
6B. I Want The Kit (IWTK): Improving an online platform for STI specimen at- home self-collection and laboratory testing
Gretchen Armington, MA
Presentation
6C. Preparing for a Home-Based Self-Sampling STI/HIV Testing Pilot Program
Ashton Morris, MPH
Johnnie Green, MBA
Presentation
6D. GetCheckedDC: A Mail-in STI Testing Pilot Program
Kenya Troutman, MPH
Presentation
6E. TakeMeHome: Implementing a novel home HIV/STI testing program
Jennifer Hecht, MPH
Presentation
Moderator: Liisa Randall, PhD
Session 7: Self-collected Micro-sampling
7A. Actionable multi-targeted STI testing using self-collect DBS for high-risk populations
Zoe Goedecke, BS
7B. Validation and prospective evaluation of mailed dried blood spot (DBS) for dual detection of HIV and syphilis using the DPP® HIV-Syphilis test
Johan H. Melendez, PhD
Presentation
7C. Clinical Utility of Hepatitis C Viral Load Detected via Dried Blood Spot Card At-Home Collection
Mariko Nakano, PhD
Presentation
7D. The implementation of self-collected MicrotainerTM specimens in a large research project—iSTAMP
Amanda J. Smith, MPH
Presentation
7E. Self-collected MicrotainerTM specimens for HIV viral load testing: a step towards HIV telemedicine
Jeffrey A. Johnson, PhD
Presentation
7F. Evaluation of self-collected MicrotainerTM specimens for measuring antiretroviral drugs
Richard E. Haaland, PhD
Presentation
Moderator: Joanne Mei, PhD